Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study

Table 5 Sensitivity analysis

	Individuals, n	Person-years	Outcome cases, n	IR, per 10,000 person-year	Crude			Adjusted^a
	Individuals, n	Person-years	Outcome cases, n	IR, per 10,000 person-year	HR	95% CI	P value	HR	95% CI	P value
Sensitivity analysis 1^b
Non-users	161,632	118,0819	1307	11.07	1			1
Proguanil/atovaquone users	16,202	119,756	104	8.68	0.77	0.64–0.94	0.009	0.78	0.63–0.95	0.016
Sensitivity analysis 2^c
Non-users	165,316	1164,939	1394	11.97	1			1
Proguanil/atovaquone users	16,500	117,889	110	9.33	0.77	0.64–0.93	0.006	0.77	0.64–0.93	0.007
Sensitivity analysis 3^d
Non-users	11,350	97,720	119	12.18	1			1
Quinine users	1135	9615	11	11.44	0.93	0.51–1.66	0.794	0.98	0.47–2.03	0.948
Sensitivity analysis 4^e
Non-users	99,040	346,280	22,848	659.81	1			1
Proguanil/atovaquone users	9904	35,130	2245	639.05	0.97	0.93–1.01	0.084	1.02	0.98–1.07	0.305

CRC colorectal cancer, IR incidence rate, HR hazard ratio, CI confidence intervals, COPD chronic obstructive pulmonary disease, IBD inflammatory bowel disease, CCI Charlson Comorbidity Index score
^aAdjusted for age at index, sex, education, birth country, income, history of inflammatory bowel disease, COPD, obesity, outpatient visits, history of colonoscopy, use of aspirin, use of statin, and CCI
^bSensitivity analysis 1: Use of proguanil and the risk of CRC among individuals with a family history of CRC lagging the follow-up time for 1 year after the administration of proguanil/atovaquone
^cSensitivity analysis 2: Use of proguanil and the risk of CRC among individuals with a family history of CRC after excluding individuals with benign colorectal tumor
^dSensitivity analysis 3: Use of quinine and the risk of CRC among individuals with a family history of CRC
^eSensitivity analysis 4: Risk of accidents among those using proguanil/atovaquone. Data on accidents available through December 2012

ISSN: 1741-7015